CHMP Recommends Against Approval of Eli Lilly's Kisunla Alzheimer's Drug -- Update
Eli Lilly, which is seeking European approval of Kisunla for the treatment of early symptomatic Alzheimer's, said it will seek re-examination by CHMP. The Indianapolis drugmaker said it remains ...
Medindia16h
Innovent Receives NMPA Breakthrough Therapy Designation for IBI363 (PD-1/IL-2a-bias Bispecific Antibody Fusion Protein) in Melanoma
PR Newswire SAN FRANCISCO and SUZHOU, China, March 30, 2025 SAN FRANCISCO and SUZHOU, China, March 30, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a ...
BioSpace3d
EU Rejects Lilly’s Alzheimer’s Drug Kisunla, Following Same Path as Rival Leqembi
The European Union’s CHMP said that the benefits of the drug, already approved in the U.S., do not outweigh the risk of ...
Morningstar3d
CHMP Recommends Against Approval of Eli Lilly's Kisunla Alzheimer's Drug — Update
A key European regulatory committee has recommended against approval of Eli Lilly's Kisunla, saying the benefits of the Alzheimer's disease drug don't outweigh its risks. The European Medicines ...
EU regulators block new Alzheimer’s drug citing potentially fatal side effects
“The benefits of Kisunla were not large enough to outweigh the risks of potentially fatal events,” the agency said, citing ...
Medical Marketing & Media4d
DTC platform LillyDirect expands to provide access for Alzheimer’s care
Eli Lilly is expanding care offerings on its direct-to-consumer (DTC) platform LillyDirect, now offering connections to ...
Science Daily6d
Engineering antibodies with a novel fusion protein
Even with significant expansion in the global market for antibodies used in clinical care and research, scientists recognize that there is still untapped potential for finding new antibodies. Many ...